RE: Everyone knows more than Mr Tom Winnifrith10 Jan 2026 11:52
Just one reminder of what Josh thought of Ashman in Sept 2025.
And As for the CEO…
And then there’s Mr Ashman, who appears to have developed a remarkable talent for PR self-harm. His habit of placing foot firmly in mouth is becoming less a quirk and more a structural risk. Most recently, his public admission — just three days after year-end — that he doesn’t know whether the company has met revenue targets would be comical, were it not so damaging. In the Big Top of AIM, this would be clownish; in a listed company, it’s frankly inexcusable.
Investors are also unforgiving of another recent gaffe: the expectation — clearly seeded in earlier communications — that the royalty veil would be lifted by the end of June. June came and went. Nothing. Not a number, not even a breadcrumb. Instead, yet more ambiguity. This is not just frustrating — it’s structurally corrosive. How can investors make rational decisions, allocate capital sensibly, or even believe the guidance they’re given, when the company appears so willing to set expectations, then silently duck them?
And let’s not forget the £4 million capital raise, with £4.8 million post Superdrug capex allegedly to fund the Axisbiotix launch — a cost estimated at £700,000. Given that even modest Croda royalties could have funded that outlay within one or two quarters, the decision raises fundamental concerns: was this capital truly necessary? Or just easier than managing the budget?